Trading Halt
Filed with ASX · · 2 pages · English
On 6ix: 6ix.com/news/trading-halt-943
Trading in the securities of Neurotech International Limited (‘NTI’) will be halted at the request of NTI, pending the release of an announcement by NTI. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of: • the commencement of normal trading on Wednesday, 17 December 2025; or • the release of the announcement to the market. NTI’s request for a trading ha
Neurotech International Ltd. on 6ix
Earlier from Neurotech International
- Neurotech receives $4.73m R&D Tax Incentive Refund
- US FDA Rare Pediatric Disease Designation in Rett syndrome
- Appendix 4E & Annual Report to shareholders
- Positive Human PK Study Results for NTI164
- NTI164 Preclinical Toxicology Studies Update
Later from Neurotech International
- Binding Commitments Received for a $4 Million Placement
- Quarterly Activities/Appendix 4C Cash Flow Report
- Approval received for NTI164 Phase 3 Clinical Study in ASD
- Positive 90-day GLP toxicology study results in non-rodents
- Appendix 4D & Half Year Report
Follow Neurotech International into a list and get an email when it puts out news.
Follow Neurotech International